1. Home
  2. SPRY vs BCSF Comparison

SPRY vs BCSF Comparison

Compare SPRY & BCSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRY
  • BCSF
  • Stock Information
  • Founded
  • SPRY 2015
  • BCSF 2015
  • Country
  • SPRY United States
  • BCSF United States
  • Employees
  • SPRY N/A
  • BCSF N/A
  • Industry
  • SPRY Biotechnology: Pharmaceutical Preparations
  • BCSF Finance/Investors Services
  • Sector
  • SPRY Health Care
  • BCSF Finance
  • Exchange
  • SPRY Nasdaq
  • BCSF Nasdaq
  • Market Cap
  • SPRY 1.6B
  • BCSF 1.0B
  • IPO Year
  • SPRY N/A
  • BCSF 2018
  • Fundamental
  • Price
  • SPRY $16.95
  • BCSF $15.25
  • Analyst Decision
  • SPRY Strong Buy
  • BCSF Buy
  • Analyst Count
  • SPRY 4
  • BCSF 2
  • Target Price
  • SPRY $28.75
  • BCSF $16.50
  • AVG Volume (30 Days)
  • SPRY 1.5M
  • BCSF 285.4K
  • Earning Date
  • SPRY 08-05-2025
  • BCSF 08-05-2025
  • Dividend Yield
  • SPRY N/A
  • BCSF 11.02%
  • EPS Growth
  • SPRY N/A
  • BCSF N/A
  • EPS
  • SPRY N/A
  • BCSF 1.75
  • Revenue
  • SPRY $97,122,000.00
  • BCSF $284,993,000.00
  • Revenue This Year
  • SPRY N/A
  • BCSF N/A
  • Revenue Next Year
  • SPRY $140.40
  • BCSF N/A
  • P/E Ratio
  • SPRY N/A
  • BCSF $8.73
  • Revenue Growth
  • SPRY 971120.00
  • BCSF N/A
  • 52 Week Low
  • SPRY $8.77
  • BCSF $13.20
  • 52 Week High
  • SPRY $18.90
  • BCSF $19.21
  • Technical
  • Relative Strength Index (RSI)
  • SPRY 55.33
  • BCSF 49.09
  • Support Level
  • SPRY $15.75
  • BCSF $14.88
  • Resistance Level
  • SPRY $18.90
  • BCSF $15.17
  • Average True Range (ATR)
  • SPRY 1.04
  • BCSF 0.25
  • MACD
  • SPRY 0.01
  • BCSF 0.01
  • Stochastic Oscillator
  • SPRY 49.26
  • BCSF 53.74

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

About BCSF Bain Capital Specialty Finance Inc.

Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan among others.

Share on Social Networks: